<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
      <journal-id journal-id-type="hwp">nng</journal-id>
      <journal-id journal-id-type="publisher-id">NNG</journal-id>
      <journal-title-group>
        <journal-title>Neurology: Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2376-7839</issn>
      <publisher>
        <publisher-name>Wolters Kluwer</publisher-name>
        <publisher-loc>Baltimore</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">31321301</article-id>
      <article-id pub-id-type="pmc">6563517</article-id>
      <article-id pub-id-type="publisher-id">NG2019010082</article-id>
      <article-id pub-id-type="doi">10.1212/NXG.0000000000000340</article-id>
      <article-categories>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>60</subject>
          <subject>72</subject>
          <subject>80</subject>
          <subject>91</subject>
          <subject>121</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Human <italic>GABRG2</italic> generalized epilepsy</article-title>
        <subtitle>Increased somatosensory and striatothalamic connectivity</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Pedersen</surname>
            <given-names>Mangor</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kowalczyk</surname>
            <given-names>Magdalena</given-names>
          </name>
          <degrees>MSc</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Omidvarnia</surname>
            <given-names>Amir</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>Review editor for Brain Imaging Methods, Frontiers in Neuroscience</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Perucca</surname>
            <given-names>Piero</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>(1) Supernus Pharmaceuticals</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>(1) Sun Pharmaceutical Industries Ltd, speaker honoraria</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>(1) Epilepsia Open, Associate Editor, 2018-present</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>(1) National Health and Medical Research Council, APP1163708, PI, 2019-present</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>(1) University of Melbourne (Melbourne International Research Scholarship) (2) University of Melbourne (Melbourne International Fee Remission Scholarship) (3) Monash University (Bridging Postdoctoral Fellowship)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>(1) Sylvia and Charles Viertel Charitable Foundation VIERCI2018014</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gooley</surname>
            <given-names>Samuel</given-names>
          </name>
          <degrees>MBBS</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Petrou</surname>
            <given-names>Steven</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>Pairnomix Inc RogCon Praxis Precision Medicines</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>PLOS Genetics, Associate Editor, 2013-Present Neurobiology of Disease, Editorial Board Member, 2008-Present</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>RogCon, Praxis</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>RogCon. $1.5M</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>2016 Ion Channel Drug Screening. TIA NCRIS. Petrou and Milligan. $39,000 Chief Investigator 2016-2018 ARC DP160104193. Clarity and MRI. Connelly and Petrou. $455,700 Chief Investigator 2016-2018 NHMRC Project APP1106027. Modelling epileptic encephalopathies using induced stem cells. Petrou and Pera $506,489 Chief Investigator 2016-2020 NHMRC Principal Research Fellowship. Targeted therapy in genetic epilepsy. Petrou. $753,300. Chief Investigator 2016-2021 NHMRC Program Grant Precision Medicine in Genetic Epilepsy. $15,000,000 Chief Investigator 2014-2021 ARC Centre of Excellence for Integrative Brain Function (CIBF). $12,000,000 Chief Investigator</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>University of Melbourne, 2015-2020 $2.5M</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>2016 DHB foundation. Glass brain imaging: Building a roadmap to the brain. Petrou S. $300K 2016 SCN2A Research Foundation, $500K</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>Pairnomix, 2015-2018 Praxis Precision Medicine, 2015-2018 RogCon, 2015-2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Scheffer</surname>
            <given-names>Ingrid E.</given-names>
          </name>
          <degrees>MBBS, PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>(1) Nutricia - Chair Scientific Advisory Board 2017 (2) UCB - Chair Scientific Advisory Board, 2017 (3) BioMarin - Chair Scientific Advisory Board 2017 (4) GSK - Scientific Advisory Board 2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>(2) GSK; Travel/Conference expenses. Honoraria, speaker 2017/2018 (3) Eisai; Honoraria, Travel/Conference expenses, speaker 2017 (4) BioMarin; Honoraria, Travel/Conference expenses 2017/2018 (5) National Research Foundation, Singapore: Travel/conference expenses, honoraria 2018 (6) Athena Diagnostics, Honoraria, Travel/Conference 2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>(1) Neurology, Editorial Board, 2014-present (2) Epilepsy Currents, Editorial Board, 2014-present (3) Epileptic Disorders, Editorial Board, 2006-present (4) Progress in Epileptic Disorders series, Editorial Board, 2005-present (5) Virtual Neuro Centre, Editorial Board, 2005-present</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>Has received revenue for: (1) Diagnostic and therapeutic methods for EFMR (2) A Diagnostic Method for Epilepsy Issued</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>(1) Ovid Therapeutics: 2018 (2) UCB: 2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other activities:</title>
                <list-item>
                  <p>(1) GW Pharmaceuticals: Participated in Epilepsy Drug Consortium as investigator 2017</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>(1) National Health and Medical Research Foundation, Australia: a) CI,Program Grant 2016-2020 b) Practitioner Fellowship 2016-2020 c) Project Grant 2016-2020 (2) CI, Centre for Research Excellence Grant, 2016-2021 (3) CI, Targeted Call for Research into Preparing Australia for the Genomics Revolution in Health Care 2016-2020 (4) National Institute of Health PI, Centres without Walls funding 'Epi4K' 2016-2020 (5) Medical Research Future Fund 2017-2021 (6) Health Research Council New Zealand 2015-2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>(1) University of Melbourne School of Health Sciences 2016</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>(1) March Of Dimes Foundation , 2015-2017 (2) Queensland Emergency Medicine Research Foundation 2016-2017</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>Diagnostic and Therapeutic Methods for EFMR (Epilepsy and Mental Retardation Limited to Females)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Berkovic</surname>
            <given-names>Samuel F.</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>UCB Pharma Eisai, Australia</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>Brain (Editorial Board ? 2000 - 2004; Advisory Board 2005-2016 ) Epileptic Disorders (1999- ) Lancet Neurology (2011- )</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>I am one of the inventors listed on a patent held by Bionomics Inc on diagnostic testing of using the SCN1A gene. International publication number WO2006/133508; filed 16/06/2006. I am one of the inventors on pending patent WO61/010176: Therapeutic Compound that relates to discovery of PCDH19 gene as the cause of familial epilepsy with mental retardation limited to females</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>Praxis</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>UCB unrestricted research grant SciGen unrestricted research grant Eisai unrestricted research grant</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020) NINDS (U01 NS077367-01; 2011-2014)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jackson</surname>
            <given-names>Graeme D.</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>Non-profit entity: Neurosciences Victoria 2003-current</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>Forum for Indian Neurology Education (FINE) Weekend Epilepsy Course 2018, Mumbai (five talks) Sun Pharmaceutical Laboratories - Commercial Airfares, accommodation, honorarium.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>?Patent # WO/2011/106821. Brain Research Institute Pty Ltd, Fernando Calamante, Jacques-Donald Tournier, Alan Connelly, Graeme Jackson ? ?Image processing system? (2013)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NHMRC Program grant(10191593) CI 2016-2020 Human Epilepsy: understanding biology to improve outcomes Berkovic SF, Jackson GD, Getz J, Connelly A, Scheffer I, O'Brien T, Petrou S, Calamante F, Reid C. NHMRC Practitioner Fellowship (1050312) GD Jackson 2014- 2018</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <aff>From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg<country>; and</country> Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, <country>Australia</country>.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence</bold> Dr. Pedersen <email>mangor.pedersen@florey.edu.au</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Go to <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/3/e340/tab-article-info">Neurology.org/NG</ext-link> for full disclosures. Funding information is provided at the end of the article.</p>
        </fn>
        <fn fn-type="other">
          <p>The Article Processing Charge was funded by the authors.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub">
        <day>07</day>
        <month>6</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>8</month>
        <year>2019</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>07</day>
        <month>6</month>
        <year>2019</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>5</volume>
      <issue>4</issue>
      <elocation-id>e340</elocation-id>
      <history>
        <date date-type="received">
          <day>28</day>
          <month>1</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>4</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
        <copyright-year>2019</copyright-year>
        <copyright-holder>American Academy of Neurology</copyright-holder>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="NG2019010082.pdf"/>
      <abstract>
        <sec>
          <title>Objective</title>
          <p>To map functional MRI (fMRI) connectivity within and between the somatosensory cortex, putamen, and ventral thalamus in individuals from a family with a GABAergic deficit segregating with febrile seizures and genetic generalized epilepsy.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We studied 5 adults from a family with early-onset absence epilepsy and/or febrile seizures and a GABA<sub>A</sub> receptor subunit gamma2 pathogenic variant (<italic>GABRG2[R43Q]</italic>) vs 5 age-matched controls. We infer differences between participants with the <italic>GABRG2</italic> pathogenic variant and controls in resting-state fMRI connectivity within and between the somatosensory cortex, putamen, and ventral thalamus.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We observed increased fMRI connectivity within the somatosensory cortex and between the putamen and ventral thalamus in all individuals with the <italic>GABRG2</italic> pathogenic variant compared with controls. Post hoc analysis showed less pronounced changes in fMRI connectivity within and between the primary visual cortex and precuneus.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Although our sample size was small, this preliminary study suggests that individuals with a <italic>GABRG2</italic> pathogenic variant, raising risk of febrile seizures and generalized epilepsy, display underlying increased functional connectivity both within the somatosensory cortex and in striatothalamic networks. This human network model aligns with rodent research and should be further validated in larger cohorts, including other individuals with generalized epilepsy with and without known GABA pathogenic variants.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>NHMRC</funding-source>
          <award-id>628952, 1060312</award-id>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>We previously reported an Australian family with a GABA type A receptor subunit gamma2 pathogenic variant (<italic>GABRG2[R43Q]</italic>) presenting with febrile seizures, febrile seizures plus, and absence epilepsy.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> This family has decreased cortical inhibition, demonstrated by transcranial magnetic stimulation,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and decreased cortical benzodiazepine receptor binding on PET.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Aligning with human data, mice with the same <italic>Gabrg2[R43Q]</italic> pathogenic variant have reduced cortical inhibition shown by deficits in GABA-mediated synaptic currents in the somatosensory cortex and anatomic changes in cortical interneuron positioning.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup></p>
    <p>Although these investigations provide clues about the mechanisms underlying the <italic>GABRG2</italic> pathogenic variant, it is unknown whether brain connectivity is affected in humans with the R43Q pathogenic variant. To study this issue, we quantified changes in functional MRI (fMRI) connectivity in individuals with this <italic>GABRG2</italic> pathogenic variant. We focused on regions previously studied in <italic>Gabrg2</italic> mice: the somatosensory cortex, the ventral thalamus, and the putamen (as a recent fMRI study in rats demonstrated that GABA<sub>A</sub> antagonists enhance connectivity of the somatosensory cortex and striatum<sup><xref rid="R6" ref-type="bibr">6</xref></sup>). Together, these 3 brain regions comprise a well-known pathway where the cortex sends excitatory signals to the putamen, which in turn exerts strong inhibitory control over the ventral thalamus via the globus pallidus and substantia nigra pars reticulata before relaying excitatory information back to the cortex.</p>
    <p>Based on previous research in humans with the <italic>GABRG2[R43Q]</italic> pathogenic variant<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> and mice with the <italic>Gabrg2[R43Q]</italic> pathogenic variant,<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> we hypothesize that fMRI connectivity within the somatosensory cortex and between subcortical regions is altered in people with a <italic>GABRG2</italic> pathogenic variant.</p>
    <sec sec-type="methods" id="s1">
      <title>Methods</title>
      <sec id="s1-1">
        <title>Participants and clinical information</title>
        <p>We recruited 5 adults from a previously reported family with the <italic>GABRG2 [R43Q]</italic> pathogenic variant<sup><xref rid="R1" ref-type="bibr">1</xref></sup> (mean age [SD]: 36.4 ± 4.2 years; clinical information in the <xref rid="T1" ref-type="table">table</xref>). They were compared with 5 age- and sex-matched controls (mean age [SD] 36.8 ± 4.1 years).</p>
        <table-wrap id="T1" orientation="portrait" position="float">
          <label>Table</label>
          <caption>
            <p>Clinical, EEG and imaging phenotype of individuals with the R43Q GABRG2 pathogenic variant<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p>
          </caption>
          <graphic xlink:href="NG2019010082t1"/>
        </table-wrap>
      </sec>
      <sec id="s1-2">
        <title>Standard protocol, approvals, and patient consents</title>
        <p>This study was approved by the Austin Human Research Ethics Committee, and participants gave written informed consent to participate.</p>
      </sec>
      <sec id="s1-3">
        <title>fMRI preprocessing</title>
        <p>We acquired 10 minutes of resting-state fMRI data on a Siemens 3T Skyra scanner with a voxel size of 3 × 3 × 3 mm and repetition time of 3 seconds. The fMRI data were slice-timing corrected, realigned, coregistered to T1 images, tissue segmented, spatially normalized, and filtered between 0.01 and 0.08 Hz. See <xref rid="R8" ref-type="bibr">reference 8</xref> for further details about our fMRI methods.</p>
      </sec>
      <sec id="s1-4">
        <title>fMRI connectivity analysis</title>
        <p>We used 2 different estimates of fMRI connectivity. (1) Regional homogeneity: to calculate voxel-averaged local connectivity within each node of our brain network model (somatosensory cortex, ventral thalamus, and putamen). This measures Kendall <italic>W</italic> correlations between a single voxel and its 26 nearby voxels in three-dimensional space. Its values range between 0 (minimal local connectivity) and 1 (maximal local connectivity). (2) Partial correlation: to calculate voxel-averaged Pearson correlations of fMRI time series between each node pair, while regressing out indirect correlation effects from all other connection pairs. Partial correlation values range between −1 (maximal negative correlation) and 1 (maximal positive correlation).</p>
      </sec>
      <sec id="s1-5">
        <title>Effect size analysis</title>
        <p>We used Hedges' <italic>g</italic> standardized effect sizes and 95th percentile confidence intervals (95% CIs) to quantify mean differences in brain connectivity between individuals with the <italic>GABRG2</italic> pathogenic variant and controls (as Hedges' <italic>g</italic> is recommended over Cohen's <italic>d</italic> in studies with a limited sample sizes). Hedges' <italic>g</italic> effect sizes <italic>=</italic> 0.2 (small); 0.5 (moderate); 0.8 (large); and 1.2 (very large).</p>
      </sec>
      <sec sec-type="data-availability" id="s1-6">
        <title>Data availability</title>
        <p>Anonymized original data will be shared by request from any qualified investigator.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="s2">
      <title>Results</title>
      <sec id="s2-1">
        <title>GABRG2: fMRI connectivity is increased within the somatosensory cortex</title>
        <p>We observed stronger fMRI connectivity within the somatosensory cortex in all individuals with the <italic>GABRG2</italic> pathogenic variant compared with controls (Hedges' <italic>g</italic> = 1.46; 95% CI = 0.43–2.41—<xref ref-type="fig" rid="F1">figure, A</xref>). Hedges' <italic>g</italic> effect sizes were lower between <italic>GABRG2</italic> and healthy controls for fMRI connectivity within the putamen (Hedges' <italic>g</italic> = 0.55; CI 95 = −0.85–1.84) and ventral thalamus (Hedges' <italic>g</italic> = 0.40; CI 95 = −0.96 to 1.70).</p>
        <fig id="F1" orientation="portrait" position="float">
          <label>Figure</label>
          <caption>
            <title>Functional connectivity within and between brain nodes in <italic>GABRG2</italic> participants displayed by purple magenta color bars and healthy controls displayed by blue cyan color bars</title>
            <p>Peak regional homogeneity across all voxels within the somatosensory cortex (A), putamen (B), and ventral thalamus (C), and partial correlations averaged across all voxels between the somatosensory cortex-putamen (D), somatosensory cortex-ventral thalamus (E), and ventral thalamus-putamen (F). Error bars denote the standard error across participants. There was little difference in head movement between groups (mean movement [SD] in <italic>GABRG2</italic> = 0.12 mm ± 0.05; mean movement [SD] in controls = 0.16 mm ± 0.04). Our 3 brain regions of interest—(1) bilateral somatosensory cortex (yellow); (2) putamen (orange); and (3) ventral thalamus (red) (G)—were delineated using the NeuroSynth database (<ext-link ext-link-type="uri" xlink:href="http://neurosynth.org/">neurosynth.org</ext-link>) incorporating findings from a multitude of previous fMRI studies describing these brain regions and their behavioral correlates, as well as their functional connectivity patterns. *A and F had large effect size.</p>
          </caption>
          <graphic xlink:href="NG2019010082f1"/>
        </fig>
      </sec>
      <sec id="s2-2">
        <title>GABRG2: fMRI connectivity is increased between the thalamus and putamen</title>
        <p>We observed stronger fMRI connectivity between the putamen and ventral thalamus in all individuals with the <italic>GABRG2</italic> pathogenic variant compared with controls (Hedges' <italic>g</italic> = 1.98; 95% CI = 0.11–3.45—<xref ref-type="fig" rid="F1">figure, F</xref>). It is worth noting that the <italic>GABRG2</italic> participant with strongest connectivity also experienced seizures into adulthood (see participant 2 in the <xref rid="T1" ref-type="table">table</xref> for more clinical information). There were no large effect sizes between <italic>GABRG2</italic> and controls for fMRI connectivity between the putamen and somatosensory cortex (Hedges' <italic>g</italic> = 0.68; 95% CI = −0.75–1.98) or the ventral thalamus and somatosensory cortex (Hedges' <italic>g</italic> = 0.26; 95% CI = −1.09 to 1.55).</p>
      </sec>
      <sec id="s2-3">
        <title>GABRG2: post hoc analysis shows less fMRI connectivity changes of the visual cortex and precuneus</title>
        <p>To test whether our primary result was specific to the somatosensory cortex, thalamus, and putamen or it reflected a “whole-brain process”, we analyzed 2 additional brain nodes: (1) primary visual cortex and (2) precuneus. We observed no large effect size in fMRI connectivity for these 2 brain regions between <italic>GABRG2</italic> and control participants. fMRI connectivity within the visual cortex: Hedges' <italic>g</italic> = 0.45; 95% CI = −0.93 to 1.74. fMRI connectivity within the precuneus: Hedges' <italic>g</italic> = 0.25; 95% CI = −1.12 to 1.56. fMRI connectivity between the visual cortex and precuneus: Hedges' <italic>g</italic> = 0.43; 95% CI = −0.95–1.72.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="s3">
      <title>Discussion</title>
      <p>We found that 5 individuals with a <italic>GABRG2</italic> pathogenic variant and a history of seizures (5/5 febrile seizures; 3/5 absence seizures) have increased fMRI connectivity within the somatosensory cortex and between the putamen and ventral thalamus compared with 5 healthy controls. This finding suggests a “network-specific” rather than a “whole-brain” effect, as our post hoc analysis revealed no difference in connectivity between <italic>GABRG2</italic> and control participants of either the primary visual cortex or the precuneus.</p>
      <p>Emerging animal research has highlighted the important role of specific brain areas in generalized epilepsy, in particular absence epilepsy where seizures are thought to originate in the somatosensory cortex<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and are modulated by thalamostriatal circuits.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Although it is not straightforward to compare animal and human studies, our findings provide preliminary evidence that somatosensory cortex and subcortical structures are hyperconnected in people with a genetic predisposition to develop febrile and also absence seizures. This finding is further supported by our previous <italic>GABRG2</italic> transcranial magnetic stimulation study—in the same family—showing neuronal hyperexcitability of the perimotor cortex.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p>
      <p>It is nontrivial to quantify whether microscale neuronal dysfunction and macroscale fMRI connectivity are related because of their vast difference in spatial scales. However, this study presented us with an opportunity to (indirectly) assess whether inhibitory neuronal dysfunction is reflected in fMRI connectivity, as we know that people with a <italic>GABRG2</italic> pathogenic variant have abnormal inhibitory GABAergic neuronal function. We postulate that our fMRI connectivity findings are related to inhibitory neuronal abnormalities, especially hyperconnectivity between the thalamus and the putamen, as the latter brain region consists almost exclusively of medium spiny inhibitory GABAergic neurons.</p>
      <p>Our small sample size is a consequence of the difficulty of recruiting a single family with a genetically homogenous disorder to the demands of an imaging study that requires travel and attendance at a single site. Despite this limitation, our preliminary findings give insight into network changes that may underlie human genetic epilepsy caused by a <italic>GABRG2</italic> pathogenic variant, and they align with results from the <italic>Gabrg2</italic> animal model, which also shows increased activity of the somatosensory cortex.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Nevertheless, our human network model based on this family with a <italic>GABRG2</italic> variant should be further validated in larger generalized epilepsy cohorts with and without known GABA pathogenic variants.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>The authors thank Susannah Bellows for recruiting the participants with the <italic>GABRG2</italic> pathogenic variant.</p>
    </ack>
    <sec sec-type="funding">
      <title>Study funding</title>
      <p content-type="funding">The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. They also acknowledge the facilities and the scientific and technical assistance of the National Imaging Facility (NIF) at the Florey node and The Victorian Biomedical Imaging Capability (VBIC). This study was supported by the National Health and Medical Research Council (NHMRC) of Australia, grant numbers 628952 and 1060312 (GJ Practitioner Fellowship) and program grant number 1091593 (S. Petrou, I. E. Scheffer, S. F. Berkovic, and G. D. Jackson).</p>
    </sec>
    <sec sec-type="disclosure">
      <title>Disclosure</title>
      <p content-type="disclosure">Disclosures available: <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/3/e340/tab-article-info">Neurology.org/NG</ext-link>.</p>
    </sec>
    <app-group>
      <app id="A1">
        <label>Appendix</label>
        <title>Authors</title>
        <p>
          <table-wrap id="TU1" orientation="portrait" position="anchor">
            <graphic xlink:href="NG2019010082tu1"/>
            <graphic xlink:href="NG2019010082tu1a"/>
          </table-wrap>
        </p>
      </app>
    </app-group>
    <glossary>
      <title>Glossary</title>
      <def-list>
        <def-item>
          <term id="G1">CI</term>
          <def>
            <p>confidence interval</p>
          </def>
        </def-item>
        <def-item>
          <term id="G2">fMRI</term>
          <def>
            <p>functional MRI</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Harkin</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Mulley</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Scheffer</surname><given-names>IE</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name></person-group>
<article-title>Childhood absence epilepsy and febrile seizures: a family with a GABAA receptor mutation</article-title>. <source>Brain</source>
<year>2003</year>;<volume>126</volume>:<fpage>230</fpage>–<lpage>240</lpage>.<pub-id pub-id-type="pmid">12477709</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Macdonell</surname><given-names>RAL</given-names></name>, <name name-style="western"><surname>Curatolo</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Marini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Reutens</surname><given-names>DC</given-names></name></person-group>
<article-title>Intracortical hyperexcitability in humans with a GABAA receptor mutation</article-title>. <source>Cereb Cortex</source>
<year>2008</year>;<volume>18</volume>:<fpage>664</fpage>–<lpage>669</lpage>.<pub-id pub-id-type="pmid">17615250</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Marini</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mulligan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tochon-Danguy</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Reutens</surname><given-names>DC</given-names></name></person-group>
<article-title>A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding</article-title>. <source>Neuroimage</source>
<year>2006</year>;<volume>32</volume>:<fpage>995</fpage>–<lpage>1000</lpage>.<pub-id pub-id-type="pmid">16875845</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>HO</given-names></name>, <name name-style="western"><surname>Reid</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Single</surname><given-names>FN</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2007</year>;<volume>104</volume>:<fpage>17536</fpage>–<lpage>17541</lpage>.<pub-id pub-id-type="pmid">17947380</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wimmer</surname><given-names>VC</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>MYS</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Petrou</surname><given-names>S</given-names></name></person-group>
<article-title>Cortical microarchitecture changes in genetic epilepsy</article-title>. <source>Neurology</source>
<year>2015</year>;<volume>84</volume>:<fpage>1308</fpage>–<lpage>1316</lpage>.<pub-id pub-id-type="pmid">25740860</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasrallah</surname><given-names>FA</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>KKDR</given-names></name>, <name name-style="western"><surname>Yeow</surname><given-names>LY</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>KH</given-names></name></person-group>
<article-title>GABAergic effect on resting-state functional connectivity: dynamics under pharmacological antagonism</article-title>. <source>Neuroimage</source>
<year>2017</year>;<volume>149</volume>:<fpage>53</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">28119136</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Currie</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Luz</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Booker</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Wyllie</surname><given-names>DJA</given-names></name>, <name name-style="western"><surname>Kind</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Daw</surname><given-names>MI</given-names></name></person-group>
<article-title>Reduced local input to fast-spiking interneurons in the somatosensory cortex in the GABAA γ2 R43Q mouse model of absence epilepsy</article-title>. <source>Epilepsia</source>
<year>2017</year>;<volume>58</volume>:<fpage>597</fpage>–<lpage>607</lpage>.<pub-id pub-id-type="pmid">28195311</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Curwood</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Vaughan</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Omidvarnia</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>GD</given-names></name></person-group>
<article-title>Abnormal brain areas common to the focal epilepsies: multivariate pattern analysis of fMRI</article-title>. <source>Brain Connect</source>
<year>2016</year>;<volume>6</volume>:<fpage>208</fpage>–<lpage>215</lpage>.<pub-id pub-id-type="pmid">26537783</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeren</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Pijn</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Van Luijtelaar</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Coenen</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Lopes da Silva</surname><given-names>FH</given-names></name></person-group>
<article-title>Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats</article-title>. <source>J Neurosci</source>
<year>2002</year>;<volume>22</volume>:<fpage>1480</fpage>–<lpage>1495</lpage>.<pub-id pub-id-type="pmid">11850474</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slaght</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Paz</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chavez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deniau</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Mahon</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Charpier</surname><given-names>S</given-names></name></person-group>
<article-title>On the activity of the corticostriatal networks during spike-and-wave discharges in a genetic model of absence epilepsy</article-title>. <source>J Neurosci</source>
<year>2004</year>;<volume>24</volume>:<fpage>6816</fpage>–<lpage>6825</lpage>.<pub-id pub-id-type="pmid">15282287</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
